OR WAIT null SECS
Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.
The need for preclinical testing expertise is growing as molecular complexity increases.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
February 05, 2024
The CDMOs are joining together to offer end-to-end development and manufacturing services for protein expression systems and viral vectors in Europe.
February 02, 2024
Strategizing a PK/PD study approach in early phase development facilitates a successful clinical progression.
Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.
January 24, 2024
Under a new alliance, KBI Biopharma and Argonaut Manufacturing Services will combine their strengths to offer end-to-end biopharma development and CGMP manufacturing solutions.
January 18, 2024
The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.
January 17, 2024
Charles River’s off-the-shelf rep/cap plasmids are intended to simplify gene therapy supply chains.
January 16, 2024
According to the Pharmapack Europe 2024 survey results, contract packaging will see growth over the coming 12 months.
January 03, 2024
Designers adopt value-added features, different materials, and enhanced coding technologies.
December 27, 2023
Andelyn Biosciences has been selected by Ultragenyx to manufacture UX111, that company’s gene therapy for treating Sanfilippo Syndrome.
December 20, 2023
Following the divestiture of its Elusys subsidiary and other non-core assets, NightHawk Biosciences will transform into a pure-play large-molecule CDMO.